beyondspring
appoints
elizabeth
czerepak
chief
financial
officer
new
york
globe
newswire
following
recent
receipt
two
breakthrough
therapy
designations
china
plinabulin
neutropenia
cin
indication
beyondspring
company
beyondspring
nasdaq
bysi
global
biopharmaceutical
company
focused
developing
innovative
cancer
therapies
transform
lives
patients
unmet
medical
needs
today
announced
appointment
elizabeth
czerepak
chief
financial
officer
effective
immediately
simultaneously
seed
therapeutics
beyondspring
new
subsidiary
focused
targeted
protein
degradation
platform
attack
previously
believed
undruggable
targets
appointed
edward
liu
chief
financial
officer
liu
also
retain
responsibilities
cfo
beyondspring
china
china
dominate
global
cin
market
billion
annual
sales
treatment
cycles
beyondspring
structured
capitalize
markets
hopes
significantly
improving
patient
care
world
said
lan
huang
beyondspring
ceo
believe
repositioning
focus
financial
capabilities
ensure
provide
best
opportunities
stakeholders
elizabeth
experience
successful
biotech
cfo
investor
public
company
board
member
large
pharmaceutical
finance
executive
prove
invaluable
team
edward
strong
global
experience
deep
understanding
global
markets
make
perfect
fit
important
new
role
seed
increasing
responsibilities
cfo
beyondspring
china
move
toward
commercialization
important
market
changes
strengthen
core
capabilities
increase
breadth
depth
pipeline
transition
integrated
r
commercial
czerepak
pharmaceutical
biotech
veteran
years
senior
finance
leadership
board
venture
capital
experience
large
pharmaceutical
companies
recently
served
cfo
chief
business
officer
genevant
sciences
also
years
venture
capital
investment
experience
former
managing
director
bear
stearns
jpmorgan
founding
general
partner
bshi
venture
fund
addition
czerepak
spent
years
leadership
positions
companies
include
roche
merck
serving
finance
strategic
planning
business
development
product
launch
teams
spearheaded
global
partner
search
culminated
basf
pharma
sale
abbott
billion
earlier
played
key
role
roche
acquisition
syntex
billion
years
also
instrumental
raising
hundreds
millions
dollars
biotech
companies
leading
investments
well
contributions
cfo
board
member
earned
mba
rutgers
university
marshall
university
recently
also
earned
corporate
director
certificate
harvard
business
school
beyondspring
reached
inflection
point
development
plinabulin
potential
greatly
improve
treatment
options
standard
care
countless
oncology
patients
across
globe
added
czerepak
look
forward
helping
company
continue
grow
move
closer
toward
commercialization
near
beyondspring
headquartered
new
york
beyondspring
global
biopharmaceutical
company
focused
developing
innovative
cancer
therapies
improve
clinical
outcomes
patients
high
unmet
medical
needs
beyondspring
lead
immune
asset
plinabulin
potent
cell
apc
inducer
currently
two
phase
clinical
trials
two
severely
unmet
medical
needs
indications
one
prevention
neutropenia
cin
frequent
cause
chemotherapy
regimen
dose
decrease
delay
downgrade
discontinuation
lead
suboptimal
clinical
outcomes
cell
lung
cancer
nsclc
treatment
egfr
patients
pipeline
drug
plinabulin
various
combination
studies
boost
antibody
effects
addition
plinabulin
beyondspring
extensive
pipeline
includes
three
assets
plinabulin
plinabulin
beyondspring
lead
asset
differentiated
immune
stem
cell
modulator
plinabulin
currently
clinical
development
increase
overall
survival
cancer
patients
well
alleviate
neutropenia
cin
durable
anticancer
benefits
plinabulin
associated
effect
potent
cell
apc
inducer
dendritic
cell
maturation
activation
chem
cell
reports
plinabulin
cin
data
highlights
ability
boost
number
hematopoietic
stem
progenitor
cells
hspcs
lsk
cells
mice
effects
hspcs
could
explain
ability
plinabulin
treat
cin
also
reduce
thrombocytopenia
increase
circulating
cells
patients
cautionary
note
regarding
statements
press
release
includes
statements
historical
facts
words
expect
anticipate
plan
believe
design
may
future
estimate
predict
objective
goal
variations
thereof
variations
words
similar
expressions
intended
identify
statements
statements
based
beyondspring
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
difficulties
raising
anticipated
amount
needed
finance
company
future
operations
terms
acceptable
company
unexpected
results
clinical
trials
delays
denial
regulatory
approval
process
results
meet
expectations
regarding
potential
safety
ultimate
efficacy
clinical
utility
product
candidates
increased
competition
market
risks
described
beyondspring
recent
form
file
securities
exchange
commission
statements
made
herein
speak
date
release
beyondspring
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
media
contacts
jeffrey
goldberger
caitlin
kasunich
kcsa
strategic
communications
jgoldberger
ckasunich
